Ascentage Received US$75M Equity Investment by Takeda
Ascentage Pharma (6855.HK) announced today that the agreed equity investment by Takeda has been closed on June 20, 2024, with all proceeds already received. Pursuant to the terms of the Agreement, Ascentage Pharma has allotted and issued an aggregate of 24,307,322 subscription shares to Takeda International at the share purchase price of HK$24.09850 (equivalent to approximately US$3.08549). About Ascentage Pharma Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK. Ascentage Pharma focuses on developing therapeutics that inhibit protei
EHA2024|Posters Featuring Three Studies of Olverembatinib
Ascentage Pharma (6855.HK) announced today that updated results from three studies of olverembatinib (HQP1351), the first China-approved third-generation BCR-ABL1 inhibitor, have been released in posters at the 2024 European Hematology Association Hybrid Congress (EHA 2024), taking place in Madrid, Spain. Building on the data reported at the 2023 American Society of Hematology Annual Meeting, Ascentage Pharma has released the updated median 1-year follow-up data of olverembatinib in patients with chronic myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). In the results, olverembatinib showed excellent durable clinical benefits and favorable long-term tolerability in patients who had been treated with multiple TKIs (including those who were resistant to
EHA2024|Updated Data of Lisaftoclax in R/R MM and AL Amyloidosis
Ascentage Pharma (6855.HK) announced today that it has released updated data of the Bcl-2 inhibitor lisaftoclax (APG-2575), one of the company’s key drug candidates, combined with novel therapeutic regimens in patients with relapsed/refractory (R/R) multiple myeloma (MM) or immunoglobulin light-chain (AL) amyloidosis, in a poster presentation at the 2024 European Hematology Association Hybrid Congress (EHA 2024), taking place in Madrid, Spain. Building on results from the study released for the first time at the 2023 American Society of Hematology Annual Meeting, the updated data presented at EHA 2024 continued to show impressive efficacy and favorable safety of lisaftoclax-based combinations, particularly the combination with pomalidomide and dexamethasone in R/R MM. Moreover, the study r
Ascentage Pharma Signs Option Agreement with Takeda
• Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas • Ascentage Pharma to receive an option payment of 100 million USD upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately 1.2 billion USD, and double-digit royalties on annual sales • Additionally, Takeda will purchase a minority interest in Ascentage Pharma Ascentage Pharma (6855 HK) announced today the signing of an option agreement with Takeda to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hema
ASCO2024|Ascentage Releases Updated Data of Lisaftoclax in WM
Ascentage Pharma (6855.HK) announced today that it has released updated results from a global, multicenter Phase Ib/II study of the Bcl-2 inhibitor lisaftoclax (APG-2575) alone or in combinations for the treatment of patients with Waldenström macroglobulinemia (WM), in a poster presentation at the 60th American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL. This is the second consecutive year in which this study of lisaftoclax, a key drug candidate in the company’s apoptosis-targeted pipeline, was selected for presentations at the ASCO Annual Meeting. The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world’s most influential and prominent scientific gathering
ASCO2024|Oral Report on Olverembatinib in SDH-Deficient GIST
Ascentage Pharma (6855.HK) announced today that it has released updated clinical data of olverembatinib (HQP1351), a third-generation tyrosine kinase inhibitor (TKI), in patients with TKI-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST), in an oral report at the 60th American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL. This is the third consecutive year in which clinical data from this study of olverembatinib were selected for presentations at the ASCO Annual Meeting. The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world’s most influential and prominent scientific gathering of the clinical oncology community. Presenting
ASCO2024|Updated Data of Lisaftoclax Plus Azacitidine in AML
Ascentage Pharma announced today that it has released the latest results from a Phase Ib/II study of its Bcl-2 inhibitor lisaftoclax (APG-2575) in combination with azacitidine (AZA) in patients with treatment-naïve (TN) or relapsed/refractory (R/R) acute myeloid leukemia (AML), in a poster presentation at the 60th American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL. The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world’s most influential and prominent scientific gathering of the clinical oncology community. Presenting clinical development progress at the ASCO Annual Meeting for the seventh consecutive year, Ascentage had four clinical studies of three of the
ASCO2024|Ascentage Releases Latest Results from Multiple Studies
Ascentage Pharma (6855.HK) announced today that its four abstracts selected for presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting are now available on ASCO’s official website. These abstracts report on the company’s three lead drug candidates, including olverembatinib (HQP1351), the first and only China-approved third-generation BCR-ABL inhibitor; lisaftoclax (APG-2575), a BCL-2 selective inhibitor; and APG-2449, a FAK/ALK/ROS1 inhibitor. Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting taking place on May 31 - June 4, 2024 in Chicago, IL. The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world’s most
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2023. During the reporting period, Ascentage Pharma made further strides in revenue generation through its commercialized product, achieved rapid progress with its patient-centric global innovation strategy, and delivered numerous milestones in clinical development and global expansion. Newly approved indication of olverembatinib expands the drug’s addressable market In 2023, Ascentage Pharma recorded a revenue of RMB222 million, most of which was attributable to product sales and milestone payments, including a revenue of RMB194 million from product sales. The company
Ascentage to Present Three Preclinical Studies at AACR 2024
Ascentage Pharma (6855.HK) announced today that the latest results from three preclinical studies of the company’s novel drug candidates olverembatinib, MDM2-p53 inhibitor alrizomadlin, FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and EED inhibitor APG-5918, have been selected for presentations at the 2024 American Association of Cancer Research Annual Meeting (AACR 2024). These abstracts are now available on the AACR’s official website. The AACR annual meeting is one of the world’s largest and longest-standing scientific gatherings in the field of cancer research. Covering some of the most cutting-edge advances in all the areas of oncology research and innovation, the annual event attracts tremendous interest from the global cancer research community. This year’s AACR annual meeting